Opportunity Information: Apply for RFA CA 21 007
This NIH/National Cancer Institute funding opportunity (RFA-CA-21-007) supports revision applications to active NCI-funded R01 projects, with the goal of speeding up or expanding the parent study by adding a new technology that was developed with NCI Innovative Molecular Analysis Technologies (IMAT) program support. In practice, it is designed for research teams who already have an ongoing R01 and want to incorporate an IMAT-supported instrument, platform, or technical approach to either broaden the original aims or accelerate the pace and impact of the existing work. A key idea behind the announcement is that promising IMAT technologies often need rigorous, independent validation in real-world research settings before they are widely adopted, and these revision awards are meant to help bridge that gap by placing emerging tools into appropriate cancer research communities.
The main scientific purpose is twofold: first, to incentivize independent testing and validation of novel IMAT-supported technologies within the context of a currently funded cancer research project; and second, to promote faster adoption of those technologies by demonstrating their value for answering important cancer biology, prevention, diagnosis, treatment, or related research questions. The FOA emphasizes that the revision should clearly build on the parent grant by either expanding the scope of the original research questions or materially accelerating progress toward the original objectives. The technology component is not meant to be a generic methods upgrade; it is specifically tied to incorporating a technical approach or instrument that originated from NCI IMAT funding, aligning the revision with IMATs broader mission of enabling innovative molecular and analytical methods for cancer research.
The award mechanism is an R01 revision (formerly known as a competing revision), meaning applicants are not proposing a brand-new standalone project. Instead, they submit a request to modify and add to an existing R01 in a way that remains anchored to the funded parent award. The announcement is labeled "Clinical Trial Optional," which signals that applicants may propose a clinical trial component if it is appropriate and justified for the revision, but a clinical trial is not required. The overall activity category is listed under Education and Health, and the program is associated with CFDA number 93.394.
Funding details in the provided source indicate an award ceiling of $150,000. The expected number of awards is not specified in the excerpt. The original closing date listed is 2021-09-29, and the FOA record creation date is 2020-11-24, indicating this was a time-bound opportunity tied to a specific receipt window.
Eligibility is broad and includes many typical NIH-eligible applicant organizations, spanning public and private institutions of higher education, nonprofits (including 501(c)(3) and non-501(c)(3)), for-profit organizations (other than small businesses), small businesses, and multiple levels of government (state, county, city/township, special district), as well as independent school districts and public housing authorities/Indian housing authorities. It also includes federally recognized Native American tribal governments and Native American tribal organizations that are not federally recognized tribal governments. The FOA also explicitly highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIS institutions, Hispanic-serving institutions, Historically Black Colleges and Universities, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-domestic (non-U.S.) entities/foreign organizations. This breadth reflects an intent to encourage participation from a wide range of research settings and communities, including institutions that serve historically underrepresented populations and organizations outside the United States when appropriate.
At its core, the opportunity is about accelerating cancer research by pairing active, question-driven R01 projects with cutting-edge IMAT-derived technologies in a way that produces clear, publishable evidence that the new technology improves capability, speed, rigor, or reach. Successful revision applications under this FOA would be expected to make a strong case that the added IMAT-supported approach is both technically and scientifically compelling for the parent projects goals, and that the revision work will meaningfully advance cancer research by validating and demonstrating the technologys utility in an independent, mission-relevant context.Apply for RFA CA 21 007
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
- This funding opportunity was created on 2020-11-24.
- Applicants must submit their applications by 2021-09-29. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $150,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is an NIH/National Cancer Institute (NCI) funding opportunity announcement (FOA) identified as RFA-CA-21-007. It supports revision applications to active NCI-funded R01 projects to speed up or expand the parent study by adding a new technology developed with NCI Innovative Molecular Analysis Technologies (IMAT) program support.
What is the main goal of the FOA?
The goal is to accelerate or broaden ongoing NCI-funded R01 research by incorporating an IMAT-supported instrument, platform, or technical approach. A central idea is to help promising IMAT technologies gain rigorous, independent validation in real research settings, which can support wider adoption in cancer research communities.
Who is this opportunity intended for?
It is designed for research teams that already have an ongoing, active NCI-funded R01 and want to incorporate an IMAT-supported technology to either (1) expand the scope of the existing work or (2) materially accelerate progress toward the original objectives of the parent award.
What type of application is required (new project vs. modification)?
This is an R01 revision application (formerly called a competing revision). It is not for proposing a brand-new standalone project. The application requests modifications and additions that remain anchored to the currently funded parent R01.
What kinds of changes should the revision propose?
The FOA emphasizes that the revision should clearly build on the parent grant by doing at least one of the following:
- Expanding the scope of the original research questions/aims, or
- Accelerating progress toward the original objectives in a meaningful way.
What is the role of IMAT-supported technology in the revision?
The technology addition is central to the FOA. The revision is meant to incorporate a technical approach or instrument that originated from NCI IMAT funding. It is not described as a general or generic methods upgrade; it should align with the IMAT mission of enabling innovative molecular and analytical methods for cancer research.
Why does the FOA emphasize independent validation of IMAT technologies?
The FOA is based on the idea that even promising IMAT technologies often need rigorous, independent testing and validation in real-world settings before broad adoption. These revision awards are intended to help bridge that gap by placing emerging IMAT tools into appropriate cancer research projects where their performance and value can be demonstrated.
What scientific areas can the revision support?
The FOA frames the technology validation and adoption goal around cancer research questions such as cancer biology, prevention, diagnosis, treatment, or related areas, as long as the work is grounded in the active NCI-funded R01 and the revision meaningfully advances the parent project.
Is a clinical trial required?
No. The FOA is labeled Clinical Trial Optional. That means a clinical trial component may be included if appropriate and well-justified for the revision, but it is not required.
What is the award ceiling (maximum amount)?
The provided information lists an award ceiling of $150,000.
How many awards will be made?
The expected number of awards is not specified in the provided excerpt.
What is the closing date for this opportunity?
The original closing date listed is 2021-09-29.
When was the FOA record created?
The FOA record creation date is listed as 2020-11-24.
What is the CFDA number associated with this program?
The program is associated with CFDA number 93.394.
What is the activity category?
The overall activity category is listed under Education and Health.
What types of organizations are eligible to apply?
Eligibility is broad and includes many NIH-eligible organization types, including:
- Public and private institutions of higher education
- Nonprofits (including 501(c)(3) and non-501(c)(3))
- For-profit organizations (other than small businesses)
- Small businesses
- State, county, city/township governments, special districts
- Independent school districts
- Public housing authorities/Indian housing authorities
- Federally recognized Native American tribal governments
- Native American tribal organizations that are not federally recognized tribal governments
Are minority-serving institutions and community-based organizations included in eligibility?
Yes. The FOA explicitly highlights additional eligible applicant types including (among others) Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, AANAPISIS institutions, and faith-based or community-based organizations.
Are non-U.S. organizations eligible to apply?
Yes. The FOA’s eligibility list explicitly includes non-domestic (non-U.S.) entities/foreign organizations, as well as U.S. territories or possessions, and regional organizations.
What makes a strong revision application under this FOA?
Based on the provided description, a strong application would be expected to clearly argue that:
- The added IMAT-supported approach is technically compelling and appropriate for the parent R01’s context.
- The added technology is scientifically compelling for answering the parent project’s cancer research questions.
- The revision will meaningfully expand scope or accelerate progress, rather than serving as a routine methods update.
- The work will produce clear evidence (e.g., publishable validation/demonstration) that the technology improves capability, speed, rigor, or reach in an independent, mission-relevant setting.
Does the revision need to be directly tied to the parent R01’s aims?
Yes. The FOA emphasizes that the revision is not a standalone effort; it must remain anchored to the parent award and should either broaden the original aims or materially accelerate progress toward the original objectives.
What is the broader program rationale behind this FOA?
The broader rationale is to speed progress in cancer research by bridging the gap between promising IMAT-derived tools and widespread use. By supporting independent, real-world validation within active R01 projects, the FOA aims to demonstrate the value of emerging technologies and promote faster adoption by the cancer research community.
Browse more opportunities from the same category: Education, Health
Next opportunity: Endangered Species Conservation - Wolf Livestock Loss Compensation and Prevention Grants
Previous opportunity: GM-20-01B Assessing the Impact of Seismic Airguns on Commercially and Recreationally-important Fish CA
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 21 007
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 21 007) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) Apply for RFA CA 21 011 Funding Number: RFA CA 21 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) Apply for RFA CA 21 010 Funding Number: RFA CA 21 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed) Apply for RFA CA 21 001 Funding Number: RFA CA 21 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) Apply for RFA CA 21 014 Funding Number: RFA CA 21 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Cellular Cancer Biology Imaging Research (CCBIR) Program (U54, Clinical Trial Not Allowed) Apply for RFA CA 21 002 Funding Number: RFA CA 21 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,250,000 |
| Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional) Apply for RFA DA 21 031 Funding Number: RFA DA 21 031 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) Apply for RFA DA 21 032 Funding Number: RFA DA 21 032 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Music and Health: Understanding And Developing Music Medicine (R21 Clinical Trial Optional) Apply for PAR 21 099 Funding Number: PAR 21 099 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R41/R42 - Clinical Trials Optional) Apply for RFA DA 21 015 Funding Number: RFA DA 21 015 Agency: National Institutes of Health Category: Education, Health Funding Amount: $256,580 |
| Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R43/R44 - Clinical Trials Optional) Apply for RFA DA 21 016 Funding Number: RFA DA 21 016 Agency: National Institutes of Health Category: Education, Health Funding Amount: $256,580 |
| Music and Health: Understanding And Developing Music Medicine (R01 Clinical Trial Optional) Apply for PAR 21 100 Funding Number: PAR 21 100 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R21 - Clinical Trials Not Allowed) Apply for RFA DA 21 041 Funding Number: RFA DA 21 041 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder (R01 - Clinical Trials Not Allowed) Apply for RFA DA 21 040 Funding Number: RFA DA 21 040 Agency: National Institutes of Health Category: Education, Health Funding Amount: $350,000 |
| International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed Apply for PAR 21 104 Funding Number: PAR 21 104 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| International Research Scientist Development Award (IRSDA) (K01 Independent Clinical Trial Required) Apply for PAR 21 105 Funding Number: PAR 21 105 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Optimizing Multi-Component Service Delivery Interventions for People with Opioid Use Disorder, Co-Occurring Conditions, and/or Suicide Risk (R01 Clinical Trials Optional) Apply for RFA MH 21 145 Funding Number: RFA MH 21 145 Agency: National Institutes of Health Category: Education, Health Funding Amount: $2,000,000 |
| HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required) Apply for RFA DA 21 030 Funding Number: RFA DA 21 030 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,750,000 |
| Pilot and Feasibility Studies in Preparation for Substance Use Prevention Trials (R34 Clinical Trial Optional) Apply for PA 21 110 Funding Number: PA 21 110 Agency: National Institutes of Health Category: Education, Health Funding Amount: $225,000 |
| Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed) Apply for RFA DA 22 004 Funding Number: RFA DA 22 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01 - Clinical Trials Not Allowed) Apply for RFA DA 22 006 Funding Number: RFA DA 22 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 21 007", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.